We utilize cutting-edge genomics approaches with three goals: 1) computational clinical oncology. We utilize computational approaches to identify driver gene mutations in cancer and determine the impact of mutations on disease course and responses to therapy. 2) mechanistic dissection of skin cancer. We study incurable skin cancers with a primary focus on cutaneous T cell lymphoma. We are using human and animal models with two goals. We seek to determine 1) the molecular basis of the aberrant immunophenotype with the goal of developing novel immunotherapies and 2) the epigenetic basis of disease with the goal of developing novel epigenetic therapies. 3) technology development. In the course of our studies, we are encountering the need for tools that are not publically available. We are therefore developing tools that we need. For the most part, these tools are designed to garner high-dimensinoal data from increasingly low numbers of cells.